Animal Pharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Animal Type, By Type of Infection, By End User, By Distribution Channel, By Region & Competition, 2021-2031F

Description

The Global Animal Pharmaceuticals Market is projected to expand from USD 28.01 Billion in 2025 to USD 39.76 Billion by 2031, registering a CAGR of 6.01%. This market covers the research, development, and sale of veterinary medications, vaccines, and medicated feed additives designed to treat and prevent diseases in both livestock and companion animals. Growth is largely fueled by the rising global demand for food security, which necessitates efficient livestock management, and the increasing need to control zoonotic pathogens. Furthermore, the strengthening emotional connection between pet owners and their animals significantly boosts spending on veterinary care. As reported by Animal Medicines Australia, the pet population in that region reached an estimated 31.6 million in 2025, with 73% of households owning a pet, underscoring the vast consumer base supporting the industry.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 28.01 Billion
Market Size 2031	USD 39.76 Billion
CAGR 2026-2031	6.01%
Fastest Growing Segment	Vaccine
Largest Market	North America

Nevertheless, market expansion faces a major hurdle due to growing regulatory scrutiny concerning antimicrobial resistance. Governments and global health bodies are implementing stricter rules on antibiotic use in livestock to protect public health, creating a rigorous regulatory landscape that pharmaceutical companies must navigate. This environment limits the sales potential of traditional antimicrobial products and forces manufacturers to bear significant costs for reformulating products and developing alternative therapies. Consequently, these compliance demands and the need for innovation in non-antibiotic solutions create substantial barriers to the seamless commercial progression of the global market.

Market Driver

The push for intensified livestock production to satisfy the growing global appetite for animal protein serves as a primary catalyst for industry growth. As farming shifts toward high-density industrial models to optimize output, herds become more vulnerable to infectious diseases, requiring rigorous protocols involving vaccines, parasiticides, and medicated feed additives. This dependence on pharmaceutical solutions is essential for maintaining animal health and adhering to international food safety standards. According to the Food and Agriculture Organization's 'Food Outlook - Biannual Report on Global Food Markets' from June 2024, global meat production is predicted to reach 371 million tonnes in 2024, a scale that highlights the necessity of pharmaceutical protection to prevent economic losses caused by disease outbreaks.

Concurrently, the market is being transformed by the trend of pet humanization and the resulting increase in healthcare spending. Pet owners increasingly regard their animals as family members, leading to a greater willingness to pay for sophisticated treatments in areas like oncology and dermatology, moving beyond mere basic care. This transition is further bolstered by the rising utilization of pet insurance, which helps offset the costs of high-value veterinary procedures. As stated by the North American Pet Health Insurance Association in its 'State of the Industry Report 2024' released in May 2024, total pet insurance premiums in the U.S. hit $3.9 billion in 2023. The sector's financial vitality, driven by these combined factors, is reflected in Zoetis Inc.'s 2024 report, which announced a full-year revenue of $8.5 billion for the fiscal year 2023.

Market Challenge

Heightened regulatory attention regarding antimicrobial resistance poses a significant obstacle to the growth of the Global Animal Pharmaceuticals Market. International health authorities and governments are applying rigorous controls that directly constrain the commercial success of antibiotic portfolios, which have traditionally provided steady revenue for veterinary pharmaceutical firms. This strict regulatory framework compels manufacturers to invest heavily in reformulating existing products to eliminate growth-promotion claims and to meet enhanced surveillance mandates, diverting financial resources that could otherwise be used to fuel broader market expansion.

The practical consequence of these restrictions is a notable decrease in the global sales volume of antimicrobial agents, as companies are forced to decrease their dependence on these drug classes. According to HealthforAnimals, the association reported in 2024 that global antibiotic sales among its members fell by 29.9% between 2015 and 2022, signaling a structural decline in this segment. This regulatory pressure effectively limits the growth prospects of therapeutic drug categories, necessitating a costly and complicated industry shift toward preventative healthcare measures rather than relying on the continued commercial success of established product lines.

Market Trends

The widespread commercial adoption of species-specific monoclonal antibodies (mAbs) is radically changing the treatment landscape by offering targeted, low-toxicity solutions for chronic ailments like osteoarthritis and skin conditions. Unlike conventional chemical medications, these biologics function through precise mechanisms that reduce systemic side effects, driving manufacturers to invest significantly in specialized infrastructure to handle rising clinical needs. This structural move toward biological manufacturing is illustrated by major supply-side initiatives; for instance, Elanco Animal Health Incorporated announced in an August 2024 press release, 'Elanco Invests $130 Million in Expansion to Boost Monoclonal Antibody Production,' that it is allocating $130 million to expand its Kansas facility specifically to advance its monoclonal antibody capabilities. This investment underscores the industry's definitive shift from broad-spectrum drugs to advanced, species-specific biological therapies.

At the same time, the integration of veterinary telehealth with digital pharmacy services is transforming how animal health products are prescribed, bought, and supplied. This trend merges virtual care platforms with automated e-commerce fulfillment, establishing a seamless cycle that improves medication adherence and secures recurring revenue for digital leaders. The strength of these automated procurement models is clear in recent financial results; Chewy, Inc. noted in its 'Fiscal Year 2023 Letter to Shareholders' in March 2024 that Autoship sales hit $8.49 billion for fiscal year 2023, accounting for over 76% of total net sales. Such volume reflects a permanent structural shift in consumer purchasing habits, moving away from sporadic in-clinic transactions toward convenient, subscription-based digital health solutions.

Key Market Players

Zoetis Inc.
Elanco Animal Health Incorporated
C.H. Boehringer Sohn AG & Co. KG
Merck & Co., Inc
Ceva Sante Animale S.A.,
Vetoquinol S.A.
Bayer AG
Virbac SA
Phibro Animal Health Corporation
Dechra Pharmaceuticals plc

Report Scope

In this report, the Global Animal Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Pharmaceuticals Market, By Product Type

Drugs
Vaccine
Medicated Feed

Animal Pharmaceuticals Market, By Animal Type

Companion Animal
Livestock Animal

Animal Pharmaceuticals Market, By Route of Administration

Oral
Parenteral
Topical

Animal Pharmaceuticals Market, By Type of Infection

Viral
Bacterial
Parasitic
Others

Animal Pharmaceuticals Market, By End User

Veterinary Hospitals
Veterinary Clinics
Point of care/In-house testing
Others

Animal Pharmaceuticals Market, By Distribution Channel

Veterinary Hospitals
Pharmacies and Drug stores
E-commerce

Animal Pharmaceuticals Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Pharmaceuticals Market.

Available Customizations:

Global Animal Pharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Pharmaceuticals Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Drugs, Vaccine, Medicated Feed)
- 5.2.2. By Animal Type (Companion Animal, Livestock Animal)
- 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
- 5.2.4. By Type of Infection (Viral, Bacterial, Parasitic, Others)
- 5.2.5. By End User (Veterinary Hospitals, Veterinary Clinics, Point of care/In-house testing, Others)
- 5.2.6. By Distribution Channel (Veterinary Hospitals, Pharmacies and Drug stores, E-commerce)
- 5.2.7. By Region
- 5.2.8. By Company (2025)
5.3. Market Map

6. North America Animal Pharmaceuticals Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Animal Type
- 6.2.3. By Route of Administration
- 6.2.4. By Type of Infection
- 6.2.5. By End User
- 6.2.6. By Distribution Channel
- 6.2.7. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Animal Pharmaceuticals Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By Animal Type
    - 6.3.1.2.3. By Route of Administration
    - 6.3.1.2.4. By Type of Infection
    - 6.3.1.2.5. By End User
    - 6.3.1.2.6. By Distribution Channel
- 6.3.2. Canada Animal Pharmaceuticals Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By Animal Type
    - 6.3.2.2.3. By Route of Administration
    - 6.3.2.2.4. By Type of Infection
    - 6.3.2.2.5. By End User
    - 6.3.2.2.6. By Distribution Channel
- 6.3.3. Mexico Animal Pharmaceuticals Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By Animal Type
    - 6.3.3.2.3. By Route of Administration
    - 6.3.3.2.4. By Type of Infection
    - 6.3.3.2.5. By End User
    - 6.3.3.2.6. By Distribution Channel

7. Europe Animal Pharmaceuticals Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Animal Type
- 7.2.3. By Route of Administration
- 7.2.4. By Type of Infection
- 7.2.5. By End User
- 7.2.6. By Distribution Channel
- 7.2.7. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Animal Pharmaceuticals Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By Animal Type
    - 7.3.1.2.3. By Route of Administration
    - 7.3.1.2.4. By Type of Infection
    - 7.3.1.2.5. By End User
    - 7.3.1.2.6. By Distribution Channel
- 7.3.2. France Animal Pharmaceuticals Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By Animal Type
    - 7.3.2.2.3. By Route of Administration
    - 7.3.2.2.4. By Type of Infection
    - 7.3.2.2.5. By End User
    - 7.3.2.2.6. By Distribution Channel
- 7.3.3. United Kingdom Animal Pharmaceuticals Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By Animal Type
    - 7.3.3.2.3. By Route of Administration
    - 7.3.3.2.4. By Type of Infection
    - 7.3.3.2.5. By End User
    - 7.3.3.2.6. By Distribution Channel
- 7.3.4. Italy Animal Pharmaceuticals Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By Animal Type
    - 7.3.4.2.3. By Route of Administration
    - 7.3.4.2.4. By Type of Infection
    - 7.3.4.2.5. By End User
    - 7.3.4.2.6. By Distribution Channel
- 7.3.5. Spain Animal Pharmaceuticals Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By Animal Type
    - 7.3.5.2.3. By Route of Administration
    - 7.3.5.2.4. By Type of Infection
    - 7.3.5.2.5. By End User
    - 7.3.5.2.6. By Distribution Channel

8. Asia Pacific Animal Pharmaceuticals Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Animal Type
- 8.2.3. By Route of Administration
- 8.2.4. By Type of Infection
- 8.2.5. By End User
- 8.2.6. By Distribution Channel
- 8.2.7. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Animal Pharmaceuticals Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By Animal Type
    - 8.3.1.2.3. By Route of Administration
    - 8.3.1.2.4. By Type of Infection
    - 8.3.1.2.5. By End User
    - 8.3.1.2.6. By Distribution Channel
- 8.3.2. India Animal Pharmaceuticals Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By Animal Type
    - 8.3.2.2.3. By Route of Administration
    - 8.3.2.2.4. By Type of Infection
    - 8.3.2.2.5. By End User
    - 8.3.2.2.6. By Distribution Channel
- 8.3.3. Japan Animal Pharmaceuticals Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By Animal Type
    - 8.3.3.2.3. By Route of Administration
    - 8.3.3.2.4. By Type of Infection
    - 8.3.3.2.5. By End User
    - 8.3.3.2.6. By Distribution Channel
- 8.3.4. South Korea Animal Pharmaceuticals Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By Animal Type
    - 8.3.4.2.3. By Route of Administration
    - 8.3.4.2.4. By Type of Infection
    - 8.3.4.2.5. By End User
    - 8.3.4.2.6. By Distribution Channel
- 8.3.5. Australia Animal Pharmaceuticals Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By Animal Type
    - 8.3.5.2.3. By Route of Administration
    - 8.3.5.2.4. By Type of Infection
    - 8.3.5.2.5. By End User
    - 8.3.5.2.6. By Distribution Channel

9. Middle East & Africa Animal Pharmaceuticals Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Animal Type
- 9.2.3. By Route of Administration
- 9.2.4. By Type of Infection
- 9.2.5. By End User
- 9.2.6. By Distribution Channel
- 9.2.7. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Animal Pharmaceuticals Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By Animal Type
    - 9.3.1.2.3. By Route of Administration
    - 9.3.1.2.4. By Type of Infection
    - 9.3.1.2.5. By End User
    - 9.3.1.2.6. By Distribution Channel
- 9.3.2. UAE Animal Pharmaceuticals Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By Animal Type
    - 9.3.2.2.3. By Route of Administration
    - 9.3.2.2.4. By Type of Infection
    - 9.3.2.2.5. By End User
    - 9.3.2.2.6. By Distribution Channel
- 9.3.3. South Africa Animal Pharmaceuticals Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By Animal Type
    - 9.3.3.2.3. By Route of Administration
    - 9.3.3.2.4. By Type of Infection
    - 9.3.3.2.5. By End User
    - 9.3.3.2.6. By Distribution Channel

10. South America Animal Pharmaceuticals Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Animal Type
- 10.2.3. By Route of Administration
- 10.2.4. By Type of Infection
- 10.2.5. By End User
- 10.2.6. By Distribution Channel
- 10.2.7. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Animal Pharmaceuticals Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By Animal Type
    - 10.3.1.2.3. By Route of Administration
    - 10.3.1.2.4. By Type of Infection
    - 10.3.1.2.5. By End User
    - 10.3.1.2.6. By Distribution Channel
- 10.3.2. Colombia Animal Pharmaceuticals Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By Animal Type
    - 10.3.2.2.3. By Route of Administration
    - 10.3.2.2.4. By Type of Infection
    - 10.3.2.2.5. By End User
    - 10.3.2.2.6. By Distribution Channel
- 10.3.3. Argentina Animal Pharmaceuticals Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By Animal Type
    - 10.3.3.2.3. By Route of Administration
    - 10.3.3.2.4. By Type of Infection
    - 10.3.3.2.5. By End User
    - 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Animal Pharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Zoetis Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Elanco Animal Health Incorporated
15.3. C.H. Boehringer Sohn AG & Co. KG
15.4. Merck & Co., Inc
15.5. Ceva Sante Animale S.A.,
15.6. Vetoquinol S.A.
15.7. Bayer AG
15.8. Virbac SA
15.9. Phibro Animal Health Corporation
15.10. Dechra Pharmaceuticals plc